INTEGRA LIFESCIENCES HOLDINGS CORP (IART) Form 8-K — Oct 2, 2026
Integra LifeSciences announced preliminary unaudited Q3 2026 results on October 2, 2026, expecting revenue of $410-412 million and adjusted EPS of $0.55-$0.59. The July flooding at its Cincinnati, Ohio manufacturing facility reduced Q3 revenue by an estimated $7 million and is expected to reduce Q4 revenue by $15-20 million. The company lowered its full-year 2026 outlook: revenue guidance was cut from $1.654-1.695 billion to $1.634-1.654 billion, and adjusted EPS guidance was cut from $2.40-2.50 to $2.30-$2.40. Full manufacturing operations at the Cincinnati facility are not expected to return until Q2 2027.
Key figures
- Revenue
- $410-412 million (Q3 2026 preliminary)
- Guidance
- FY2026 revenue lowered from $1.654-1.695B to $1.634-1.654B; adjusted EPS lowered from $2.40-2.50 to $2.30-2.40; operating cash flow ~$190-200M FY, >$85M Q3
- Q3 adjusted eps
- $0.55-$0.59
- Q3 revenue impact flooding
- $7 million
- Q4 revenue impact flooding
- $15-20 million
- Full manufacturing recovery
- Q2 2027
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.